

Acknowledgement to Referees

© Springer Nature Switzerland AG 2018

Dear Reader,

As we reach the final issue of *BioDrugs* for 2018, we wish to reflect on another successful year's achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2018 was a successful year for *BioDrugs*. Over 50 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:

Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. McKinnon, R.A., Cook, M., Liauw, W. et al. *BioDrugs* (2018) 32: 27. <https://doi.org/10.1007/s40259-017-0256-z>

Anticalin[®] Proteins as Therapeutic Agents in Human Diseases. Rothe, C. & Skerra, A. *BioDrugs* (2018) 32: 233. <https://doi.org/10.1007/s40259-018-0278-1>

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. Husain, B. & Ellerman, D. *BioDrugs* (2018) 32: 441. <https://doi.org/10.1007/s40259-018-0299-9>

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained. Aapro, M., Krendyukov, A., Schiestl, M. et al. *BioDrugs* (2018) 32: 129. <https://doi.org/10.1007/s40259-018-0262-9>

Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. O'Callaghan, J., Griffin, B.T., Morris, J.M. et al. *BioDrugs* (2018) 32: 267. <https://doi.org/10.1007/s40259-018-0281-6>

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade[®]. Melsheimer, R., Calmann, M., DeRitis, A. et al. *BioDrugs* (2018) 32: 405. <https://doi.org/10.1007/s40259-018-0300-7>

Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. Zozaya, N., Martínez-Galdeano, L., Alcalá, B. et al. *BioDrugs* (2018) 32: 281. <https://doi.org/10.1007/s40259-018-0284-3>

Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future. Devarasetty, M., Mazzocchi, A.R. & Skardal, A. *BioDrugs* (2018) 32: 53. <https://doi.org/10.1007/s40259-017-0258-x>

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study. Stoppa, G., D'Amore, C., Conforti, A. et al. *BioDrugs* (2018) 32: 367. <https://doi.org/10.1007/s40259-018-0293-2>

Guselkumab for the Treatment of Psoriasis. Machado, Á. & Torres, T. *BioDrugs* (2018) 32: 119. <https://doi.org/10.1007/s40259-018-0265-6>

Social media sharing of information is becoming more important and is another metric with which to measure the reach of articles. This year the following articles published in *BioDrugs* scored highly on the Altmetric system:

Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. O'Callaghan, J., Griffin, B.T., Morris, J.M. et al. *BioDrugs* (2018) 32: 267. <https://doi.org/10.1007/s40259-018-0281-6>

Anticalin[®] Proteins as Therapeutic Agents in Human Diseases. Rothe, C. & Skerra, A. *BioDrugs* (2018) 32: 233. <https://doi.org/10.1007/s40259-018-0278-1>

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways. Sasi-kumar, P.G. & Ramachandra, M. *BioDrugs* (2018) 32: 481. <https://doi.org/10.1007/s40259-018-0303-4>

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. Husain, B. & Ellerman, D. *BioDrugs* (2018) 32: 441. <https://doi.org/10.1007/s40259-018-0299-9>

The quality of articles published in the journal is also reflected in its most recent impact factor of 3.825, and a percentile ranking of 81% in the Pharmacology and Pharmacy category.

Other journals in the Adis Premier Journals Portfolio (<http://www.springer.com/gp/adis>) continue to prosper with substantial increases in usage year on year. In addition, this year has seen *Applied Health Economics and Health Policy* receive its first impact factor.

We thank the authors who have contributed articles to *BioDrugs* over the course of 2018. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for *BioDrugs* in the last 12 months:

Samuel Adegbola, UK	Birgitte de Blasio, Norway
Georges Adunlin, USA	Paul Declerck, Belgium
Aikaterini Alexaki, USA	Fabien Despas, France
Ayad K. Ali, USA	Souvik Dey, USA
Filipe Araujo, Portugal	Brett Doble, UK
Ramon Arens, the Netherlands	Christian Domingo, Spain
Raja Atreya, Germany	Kyla Driscoll, USA
George Bakalos, Switzerland	Bruno A. Duso, Italy
Adam W. Barb, USA	Hans C. Ebbers, the Netherlands
Daniel G. Bausch, UK	Benjamin Ehst, USA
David S.H. Bell, USA	Niklas Ekman, Finland
Fernando Bermejo, Spain	Arielle Elkrief, Canada
Ulrich Bickel, USA	Johan G. Eriksson, Finland
Niels W. Boone, the Netherlands	Mahyar Etminan, Canada
Maria Bova, Italy	Stefano Fais, Italy
Michael Brehm, USA	Steven R. Feldman, USA
Vitalis Briedis, Lithuania	Jackie Ferguson, USA
Wallace Brownlee, UK	Nicolas Fischer, Switzerland
Anna E. Bucsecs, Austria	Mathurin Flamant, France
Benedetta Bussolati, Italy	Julien Freitag, Australia
Gilberto Castañeda Hernández, Mexico	Wayne Furman, USA
Jongwha Chang, USA	Yan-Feng Gao, China
Andrea Chiricozzi, Italy	Antonio Garcia-Merino, Spain
Kian Fan Chung, UK	Pere Gascon, Spain
Hillel P. Cohen, USA	Salah Ghabri, France
Stanley B. Cohen, USA	Alessandra Gianoncelli, Italy
Paul Cornes, UK	Thijs J. Giezen, the Netherlands
Ben Cowper, UK	David E. Gilham, Belgium
Tünde Csepany, Hungary	Ellen Goldman, USA
Paola M. Cutroneo, Italy	David J. Goldsmith, UK
Romano Danesi, Italy	Jens Greve, Germany
Tapan Das, USA	Alastair Greystoke, UK
Ronilda D'Cunha, USA	Roberta Gualtierotti, Italy

Matthew M. Gubin, USA
László Gulácsi, Hungary
Lora Hamuro, USA
Kenta Haraya, Japan
Gaya Hettiarachchi, USA
Tad Holak, Poland
David J. Hunter, Australia
Jin Ah Hwang, Republic of Korea
Shu-ichi Ikeda, Japan
Ylenia Ingrassiotta, Italy
Lulu Jia, China
Bernd Jilma, Austria
Gareth W. Jones, UK
Jagath Junutula, USA
Leonid Kagan, USA
Hye-Na Kang, Switzerland
Kaan Kavakli, Turkey
Frieder Keller, Germany
Chava Kimchi-Sarfaty, USA
Agnete Kirkeby, Denmark
Tadamitsu Kishimoto, Japan
Gary Kobinger, Canada
Andriy Krendyukov, Germany
Pekka Kurki, Finland
Byungsuk Kwon, Republic of Korea
Tamar Lasky, USA
Roger Leblanc, USA
Sang Joon Lee, Republic of Korea
Roberto Leone, Italy
Victor Levin, USA
Haojun Liang, China
Robert Likic, Croatia
Gerald P. Linette, USA
Liming Liu, USA
Stephen Liu, USA
Francesco Locatelli, Italy
Lorena Lorefice, Italy
Nicholas J. Lowe, UK
Michael Makris, UK
Charles J. Malemud, USA
Spencer D. Martin, Canada
Inmaculada Martinez Sager, Germany
Josephine A. Mauskopf, USA
Kelley Mayden, USA
Tim Menzen, Germany
Meriem Messaoudene, Canada
Chad Mirkin, USA
Massimo Morbidelli, Switzerland
Shahrul Mt-Isa, UK
Stephen Muench, UK
Giorgio Mustacchi, Italy
Peter P. Nash, Australia
Reza Nejadnik, Germany
Dario Neri, Switzerland
Patrick Neven, Belgium
Chee-Keng Ng, USA
Naoyuki Nogami, Japan
Paul J. Orchard, USA
John J. O'Shea, USA
Ramesh Palaparthi, USA
Nikolaos Papanas, Greece
Vidhya Parameswaran, Canada
Maria Kristina Parr, Germany
Andrew Pickett, UK
Christian Pifl, Austria
Sandra Prior, UK
Lluís Puig, Spain
Wolfgang F. Richter, Switzerland
Wolf Rogowski, Germany
Stefan Rose-John, Germany
Gargi Roy, USA
Thomas Sakmar, USA
Atsushi Sakuraba, USA
Melody Sauerborn, Germany
Zuben Sauna, USA
Justin M. Scheer, USA
Huub Schellekens, the Netherlands
Marc Scherlinger, France
Gerold Schuler, Germany
Tim Schutte, the Netherlands
Nicolo Scuderi, Italy
Monica Serban, USA
Anil Shanker, USA
Susan Sharfstein, USA
Lenny Shultz, USA
Marina Simian, Argentina
Susan F. Slovin, USA
Justin Stebbing, UK
Stella Stergiopoulos, USA
Michael A. Stoto, USA
Marion Subklewe, Germany
Silvio Tafuri, Italy
Yoshiya Tanaka, Japan
Peter C. Taylor, UK
Fabio Teixeira, Portugal
Neil Templeton, USA
Darren Tomlinson, UK
Tiago Torres, Portugal
Jean-Hugues Trouvin, France
Marco Tuccori, Italy
Susumu Uchiyama, Japan
Eduard Urich, Switzerland
Leon A.G. van Aerts, the Netherlands
Eline van Overbeeke, Belgium
Arnold G. Vulto, the Netherlands
Ed Waddingham, UK

Martina Weise, Germany
Gary Wong, China
Yuhe Renee Yang, USA

Dae Hyun Yoo, Republic of Korea
John Zalcborg, Australia
Andrew Zloza, USA

In addition, we would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

L. Bergmann, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany
E. De Clercq, Rega Instituut, Leuven, Belgium
G.D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA
T.R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA
T.M. Ganey, Vivex Biomedical, Atlanta, GA, USA
A. Ganser, Hannover Medical School, Hannover, Germany
H-P. Gerber, 3T Biosciences, Palo Alto, CA, USA
B. Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany
F. Guilhot, Université de Poitiers, Poitiers, France
W.H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA
S.L. Lightman, Moorfields Eye Hospital, London, UK
P. Moingeon, Stallergenes, Paris, France
D. Müller, Universität Stuttgart, Stuttgart, Germany
J.L. Murray, University of Texas MD Anderson Cancer Center, Houston, TX, USA
W. Park, Inha University Medical School, Incheon, Republic of Korea
C. Picado, Hospital Clinic de Barcelona, Barcelona, Spain
T. Schirrmann, YUMAB GmbH, Braunschweig, Germany
C.A. Stein, City of Hope Medical Center, Duarte, CA, USA
R.C. Stevens, University of Southern California, Los Angeles, CA, USA
W.R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA
B.A. Sullenger, Duke University Medical Center, Durham, NC, USA
J. Terrett, Crispr Therapeutics, Inc., Cambridge, MA, USA
P. Trzonkowski, Medical University of Gdansk, Gdansk, Poland
J.W. Van der Meer, University Medical Center St Radboud, Nijmegen, the Netherlands

We do hope that you have found the articles published throughout the year in *BioDrugs* to be interesting and informative. The editorial schedule for 2019 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes
Kathy Fraser
Editor